Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Movement Disorders : Official Journal of the Movement Disorder Society|November 29, 2025
Cerebrospinal Fluid Biomarkers of NLRP3 Pathway, Immune Dysregulation, and Neurodegeneration in Parkinson's Disease: A Meta-AnalysisAlina-Măriuca Marinescu, Venissa Machado, Gennaro Pagano, et al.
Respiratory Medicine|February 8, 2018
Efficacy and safety of lebrikizumab in adult patients with mild-to-moderate asthma not receiving inhaled corticosteroidsPhilip Korenblat, Edwin Kerwin, Igor Leshchenko, et al.
Research Synthesis Methods|June 9, 2015
Methodological quality of meta-analyses: matched-pairs comparison over time and between industry-sponsored and academic-sponsored reportsPeter W Lane, Julian P T Higgins, Betsy Anagnostelis, et al.
Research Synthesis Methods|June 9, 2015
A tool to assess the quality of a meta-analysisJulian P T Higgins, Peter W Lane, Betsy Anagnostelis, et al.
European Heart Journal|March 19, 2014
The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trialKausik K Ray, Marc Ditmarsch, David Kallend, et al.
Clinical and Translational Allergy|July 18, 2022
Efficacy, safety, and tolerability of lebrikizumab in adolescent patients with uncontrolled asthma (ACOUSTICS)Stanley J Szefler, Graham Roberts, Adalberto S Rubin, et al.
Nature Medicine|April 15, 2024
Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson's diseaseGennaro Pagano, Kirsten I Taylor, Judith Anzures Cabrera, et al.
Lancet (London, England)|May 28, 2026
Efficacy and safety of intravenous prasinezumab in individuals with early-stage Parkinson's disease on stable symptomatic monotherapy (PADOVA): a phase 2b, multicentre, randomised, double-blind, placebo-controlled studyTania Nikolcheva, Gennaro Pagano, Judith Anzures-Cabrera, et al.
NPJ Digital Medicine|June 16, 2025
Exploratory digital outcome measures of motor sign progression in Parkinson's disease patients treated with prasinezumabKirsten I Taylor, Florian Lipsmeier, Marzia A Scelsi, et al.
Frontiers in Neurology|October 18, 2021
A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline DataGennaro Pagano, Frank G Boess, Kirsten I Taylor, et al.
Pageof 3